Eledon Pharmaceuticals, Inc. (ELDN)
NASDAQ: ELDN · Real-Time Price · USD
3.570
+0.110 (3.18%)
At close: Jun 11, 2026, 4:00 PM EDT
3.630
+0.060 (1.68%)
Pre-market: Jun 12, 2026, 7:41 AM EDT
Eledon Pharmaceuticals Employees
Eledon Pharmaceuticals had 33 employees as of December 31, 2025. The number of employees increased by 2 or 6.45% compared to the previous year.
Employees
33
Change (1Y)
2
Growth (1Y)
6.45%
Revenue / Employee
n/a
Profits / Employee
-$2,368,091
Market Cap
275.97M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 33 | 2 | 6.45% | 33 | 0 |
| Dec 31, 2024 | 31 | 11 | 55.00% | 31 | 0 |
| Dec 31, 2023 | 20 | 3 | 17.65% | 20 | 0 |
| Dec 31, 2022 | 17 | 5 | 41.67% | 17 | 0 |
| Dec 31, 2021 | 12 | 2 | 20.00% | 12 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Bicycle Therapeutics | 288 |
| Rocket Pharmaceuticals | 202 |
| Nautilus Biotechnology | 127 |
| Niagen Bioscience | 117 |
| Armata Pharmaceuticals | 61 |
| Immuneering | 55 |
| Surrozen | 44 |
| Inhibikase Therapeutics | 35 |
ELDN News
- 4 days ago - Eledon Pharmaceuticals announces updated results from tegoprubart trial - TheFly
- 4 days ago - Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine - GlobeNewsWire
- 7 days ago - Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions - GlobeNewsWire
- 22 days ago - Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress - GlobeNewsWire
- 4 weeks ago - Eledon Pharmaceuticals reports Q1 EPS (33c), consensus (23c) - TheFly
- 4 weeks ago - Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewsWire
- 4 weeks ago - Eledon Pharmaceuticals Earnings release: Q1 2026 - Filings
- 4 weeks ago - Eledon Pharmaceuticals Quarterly report: Q1 2026 - Filings